Cingulate (CING) Competitors $3.79 +0.09 (+2.43%) Closing price 04:00 PM EasternExtended Trading$3.76 -0.03 (-0.79%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. QNCX, WHWK, ATRA, ABOS, EXOZ, IMUX, ASRT, PYXS, KALA, and ARTVShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Quince Therapeutics (QNCX), Whitehawk Therapeutics (WHWK), Atara Biotherapeutics (ATRA), Acumen Pharmaceuticals (ABOS), eXoZymes (EXOZ), Immunic (IMUX), Assertio (ASRT), Pyxis Oncology (PYXS), KALA BIO (KALA), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Its Competitors Quince Therapeutics Whitehawk Therapeutics Atara Biotherapeutics Acumen Pharmaceuticals eXoZymes Immunic Assertio Pyxis Oncology KALA BIO Artiva Biotherapeutics Quince Therapeutics (NASDAQ:QNCX) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Which has more volatility and risk, QNCX or CING? Quince Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.76, indicating that its share price is 176% less volatile than the S&P 500. Do analysts rate QNCX or CING? Quince Therapeutics presently has a consensus target price of $8.14, suggesting a potential upside of 407.34%. Cingulate has a consensus target price of $26.25, suggesting a potential upside of 592.61%. Given Cingulate's higher possible upside, analysts plainly believe Cingulate is more favorable than Quince Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is QNCX or CING more profitable? Quince Therapeutics' return on equity of -187.49% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -187.49% -42.47% Cingulate N/A -232.16%-132.07% Do institutionals & insiders have more ownership in QNCX or CING? 30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 20.3% of Quince Therapeutics shares are owned by insiders. Comparatively, 4.0% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor QNCX or CING? In the previous week, Quince Therapeutics and Quince Therapeutics both had 3 articles in the media. Quince Therapeutics' average media sentiment score of 1.21 beat Cingulate's score of -0.10 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, QNCX or CING? Quince Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$56.83M-$1.09-1.47CingulateN/AN/A-$15.55M-$4.10-0.92 SummaryQuince Therapeutics beats Cingulate on 9 of the 12 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulateMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.03M$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E RatioN/A21.0283.0126.65Price / SalesN/A379.56503.05163.66Price / CashN/A43.5325.7028.92Price / Book1.638.1210.796.52Net Income-$15.55M-$53.35M$3.29B$266.21M7 Day Performance-3.81%0.05%0.01%-0.76%1 Month Performance-32.44%7.08%7.06%3.83%1 Year Performance-43.52%11.92%50.09%24.39% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.9024 of 5 stars$3.79+2.4%$26.25+592.6%-47.1%$20.03MN/A0.0020QNCXQuince Therapeutics3.7362 of 5 stars$1.60+3.9%$8.14+408.9%+132.3%$85.94MN/A-1.4760Positive NewsWHWKWhitehawk TherapeuticsN/A$1.81+2.0%N/AN/A$85.07M$25.98M-30.0840Positive NewsATRAAtara Biotherapeutics4.4714 of 5 stars$12.05-2.5%$21.00+74.3%+85.5%$84.63M$128.94M-28.02330News CoverageABOSAcumen Pharmaceuticals2.8528 of 5 stars$1.36+3.8%$7.00+414.7%-43.3%$82.38MN/A-0.6020EXOZeXoZymesN/A$9.70flatN/AN/A$81.36M$70K0.0029Gap UpIMUXImmunic2.7611 of 5 stars$0.82-5.7%$7.50+814.6%-42.5%$80.89MN/A-0.8770Analyst RevisionASRTAssertio2.0943 of 5 stars$0.84+3.0%$2.38+184.4%-27.0%$80.37M$124.96M-1.8620High Trading VolumePYXSPyxis Oncology1.3761 of 5 stars$1.28-3.8%$8.67+577.1%-57.3%$79.38M$16.15M-0.8060Analyst ForecastGap UpKALAKALA BIO2.8463 of 5 stars$11.22+5.9%$13.00+15.9%+148.1%$78.78M$3.89M-1.6530News CoverageAnalyst UpgradeHigh Trading VolumeARTVArtiva Biotherapeutics3.2451 of 5 stars$3.15-0.3%$17.00+439.7%-71.1%$76.94M$250K0.0081Positive NewsGap Up Related Companies and Tools Related Companies Quince Therapeutics Competitors Whitehawk Therapeutics Competitors Atara Biotherapeutics Competitors Acumen Pharmaceuticals Competitors eXoZymes Competitors Immunic Competitors Assertio Competitors Pyxis Oncology Competitors KALA BIO Competitors Artiva Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
